Disease-modifying therapy and adjuvant support in complex therapy of chronic non-specific low back pain. Resolution of the Multidisciplinary Board of Experts

The objective of the multidisciplinary expert panel consensus was to determine the place and role of disease-modifying and adjuvant therapy for osteoarthritis of the facet joints in patients with nonspecific back pain. Key issues in the management of patients with chronic nonspecific back pain were updated, taking into account its epidemiology, new data about risk factors and molecular pathogenesis, modern international and Russian clinical recommendations and algorithms for the management of patients with low back pain, analysis of pharmacology and evidence-based data medicine about the effectiveness and safety of the use of disease-modifying osteoarthritis drugs (DMOADs) in these patients. The Council of Experts presents an optimized algorithm for managing these patients using courses of therapy with the parenteral form of the drug highly purified chondroitin sulfate Chondroguard (Pharmaceutical company «Sotex» CJSC, Russia), glucosamine sulfate (Sustagard Arthro and Sustagard, Pharmaceutical company «Sotex» CJSC, Russia), and also with the use of nutritional support of pharmaconutraceuticals «Chondroguard TRIO» (dietary supplement) and with combined nutraceuticals, including vitamins D3 (cholecalciferol) and K2 (menaquinone). The consensus resolution noted the need to discuss the inclusion of active DMOADs compounds and adjuvant therapy for osteoarthritis in clinical guidelines for the management of patients with chronic musculoskeletal low back pain for the purpose of its effective and safe control and prevention.